Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North Carolina

Dan-Yu Lin, Yu Gu, Bradford Wheeler, Hayley Young, Shannon Holloway, Shadia Khan Sunny, Zack Moore, Donglin Zeng
doi: https://doi.org/10.1101/2021.10.25.21265304
Dan-Yu Lin
1University of North Carolina at Chapel Hill Gillings School of Global Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lin@bios.unc.edu
Yu Gu
1University of North Carolina at Chapel Hill Gillings School of Global Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradford Wheeler
2North Carolina Department of Health and Human Services
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hayley Young
2North Carolina Department of Health and Human Services
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shannon Holloway
3North Carolina State University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shadia Khan Sunny
2North Carolina Department of Health and Human Services
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zack Moore
2North Carolina Department of Health and Human Services
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donglin Zeng
1University of North Carolina at Chapel Hill Gillings School of Global Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background The duration of protection afforded by Covid-19 vaccines in the United States is unclear. Whether the recent increase of breakthrough infections was caused by waning immunity to the primary vaccination or by emergence of new variants that are more highly transmissible is also unknown.

Methods We extracted data on vaccination histories and clinical outcomes (Covid-19, hospitalization, death) for the period from December 13, 2020 through September 8, 2021 by linking data from the North Carolina COVID-19 Surveillance System and COVID-19 Vaccine Management System covering ∼10.6 million residents statewide. We used the Kaplan-Meier method to estimate the effectiveness of the BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna), and Ad26.COV2.S (Janssen) vaccines in reducing the incidence of Covid-19 over successive post-vaccination time periods, producing separate estimates for individuals vaccinated during different calendar periods. In addition, we used Cox regression with time-dependent vaccination status and time-varying hazard ratios to estimate the effectiveness of the three vaccines in reducing the hazard rates or current risks of Covid-19, hospitalization, and death, as a function of time elapsed since the first dose.

Results For the Pfizer two-dose regimen, vaccine effectiveness in reducing the current risk of Covid-19 ramps to a peak level of 94.9% (95% confidence interval [CI], 94.5 to 95.2) at 2 months (post the first dose) and drops to 70.1% (95% CI, 68.9 to 71.2) after 7 months; effectiveness in reducing the current risk of hospitalization ramps to a peak level of 96.4% (95% CI, 94.7 to 97.5) at 2 months and remains at 87.7% (95% CI, 84.3 to 90.4) at 7 months; effectiveness in reducing the current risk of death ramps to 95.9% (95% CI, 92.9 to 97.6) at 2 months and is maintained at 88.4% (95% CI, 83.0 to 92.1) at 7 months. For the Moderna two-dose regimen, vaccine effectiveness in reducing the current risk of Covid-19 ramps to a peak level of 96.0% (95% CI, 95.6 to 96.4) at 2 months and drops to 81.9% (95% CI, 81.0 to 82.7) after 7 months; effectiveness in reducing the current risk of hospitalization ramps to a peak level of 97.5% (95% CI, 96.3 to 98.3) at 2 months and remains at 92.3% (95% CI, 89.7 to 94.3) at 7 months; effectiveness in reducing the current risk of death ramps to 96.0% (95% CI, 91.9 to 98.0) at 3 months and remains at 93.7% (95% CI, 90.2 to 95.9) at 7 months. For the Janssen one-dose regimen, effectiveness in reducing the current risk of Covid-19 ramps to a peak level of 79.0% (95% CI, 77.1 to 80.7) at 1 month and drops to 64.3% (95% CI, 62.3 to 66.1) after 5 months; effectiveness in reducing the current risk of hospitalization ramps to a peak level of 89.8% (95% CI, 78.8 to 95.1) at 2 months and stays above 80% through 5 months; effectiveness in reducing the current risk of death ramps to 89.4% (95% CI, 52.3 to 97.6) at 3 months and stays above 80% through 5 months. For all three vaccines, the ramping and waning patterns are similar for individuals who were vaccinated at different dates, and across various demographic subgroups (age, sex, race/ethnicity, geographic region, county-level vaccination rate).

Conclusions The two mRNA vaccines are remarkably effective and durable in reducing the risks of hospitalization and death. The Janssen vaccine also offers a high level of protection against hospitalization and death. The Moderna vaccine is significantly more durable than the Pfizer vaccine in reducing the risk of Covid-19. Waning vaccine effectiveness is caused primarily by declining immunity rather than emergence of new variants. It would be worthwhile to investigate the effectiveness of the Janssen vaccine as a two-dose regimen, with the second dose given approximately 1-2 months after the first dose.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

NIAID

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of North Carolina Office of Human Research Ethics

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the North Carolina Department of Public Health

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North Carolina
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North Carolina
Dan-Yu Lin, Yu Gu, Bradford Wheeler, Hayley Young, Shannon Holloway, Shadia Khan Sunny, Zack Moore, Donglin Zeng
medRxiv 2021.10.25.21265304; doi: https://doi.org/10.1101/2021.10.25.21265304
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North Carolina
Dan-Yu Lin, Yu Gu, Bradford Wheeler, Hayley Young, Shannon Holloway, Shadia Khan Sunny, Zack Moore, Donglin Zeng
medRxiv 2021.10.25.21265304; doi: https://doi.org/10.1101/2021.10.25.21265304

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (417)
  • Anesthesia (93)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (398)
  • Epidemiology (8597)
  • Forensic Medicine (4)
  • Gastroenterology (391)
  • Genetic and Genomic Medicine (1775)
  • Geriatric Medicine (170)
  • Health Economics (376)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (198)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10354)
  • Intensive Care and Critical Care Medicine (554)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (934)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (256)
  • Pediatrics (541)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1788)
  • Public and Global Health (3877)
  • Radiology and Imaging (629)
  • Rehabilitation Medicine and Physical Therapy (324)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (171)
  • Sports Medicine (159)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)